PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?

Moreno-Vicente, Julia, Beers, Stephen A. and Gray, Juliet C. (2019) PD-1/PD-L1 blockade in paediatric cancers: What does the future hold? Cancer Letters, 457, 74-85. (doi:10.1016/j.canlet.2019.04.025).

Abstract

Checkpoint blockade (CPB) immunotherapy has shown unprecedented success in a wide range of adult malignancies, and is increasingly being employed in the treatment of advanced cancers. However, the experience in the paediatric population remains limited and the small number of single agent studies reported have shown disappointing response rates. Paediatric cancers offer unique challenges that can hinder the translation of CPB into the paediatric clinic, and combinational therapies are likely to be needed to achieve therapeutic success. As the number of paediatric trials using CPB rapidly increases, understanding the challenges that these agents may encounter in this population is of special significance to allow the design of optimal combinatorial strategies for each tumour type. Here, we offer an overview of the unique biological and immunological features of paediatric cancers as compared to adult malignancies, and how these might impact the overall success of CPB in the paediatric population. We review the growing body of pre-clinical and clinical experiences to date, and discuss future strategies involving the combination of CPB with traditionally used therapies (chemotherapy and radiotherapy) or with other newly developed immunotherapies.

This record has no associated files available for download.

Contributors

Author: Stephen A. Beers

Author: Juliet C. Gray

Download statistics